The Global Fund has pledged $700 million over the next three years to combat communicable diseases in Uganda, reinforcing its partnership with Uganda’s Health Ministry. Established in 2002, the Global Fund, headquartered in Geneva, operates as an innovative financing mechanism dedicated to mitigating the impact of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis, and malaria in low- and middle-income countries. With a cumulative investment of $2.9 billion and an additional $700 million earmarked for the coming years, the Fund focuses on addressing prevalent diseases and unique challenges such as mosquito resistance and HIV/AIDS prevention. This commitment allays concerns regarding potential funding reductions amidst policy controversies, ensuring continued support for patients affected by HIV/AIDS, tuberculosis, and malaria in Uganda.
During discussions, key areas for potential procurement were outlined, including Antiretroviral Drugs for HIV treatment, rapid diagnostic tests for malaria and HIV, long-lasting insecticidal nets, and medical gloves. In response, the Global Fund expressed readiness to engage local markets to ensure a steady supply of essential medical supplies while addressing cost considerations and market competitiveness.